99.04MMarket Cap-1286P/E (TTM)
2.230High2.180Low47.76KVolume2.200Open2.190Pre Close105.54KTurnover0.14%Turnover RatioLossP/E (Static)45.02MShares3.62052wk High-6.29P/B76.86MFloat Cap1.36052wk Low--Dividend TTM34.94MShs Float105.000Historical High--Div YieldTTM2.28%Amplitude1.300Historical Low2.209Avg Price1Lot Size
Checkpoint Therapeutics Stock Forum
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the presentation of longer-term data from its pivotal trial of cosibelimab, its anti-programmed death ligand-1 ("PD-L1") antibod...
Checkpoint Therapeutics, Inc. (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, has recently announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for cosibelimab. This investigational anti-PD-L1 a...
$OptiNose (OPTN.US)$
when are the next date for $Checkpoint Therapeutics (CKPT.US)$ , $Fortress Biotech (FBIO.US)$ , and $Brainstorm Cell Therapeutics (BCLI.US)$ ?
all of these stocks currently not good fundamentally... some even minus PBV
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
Hope miracle happens suddenly shows up an acquisition news like $Gracell Biotechnologies (GRCL.US)$ by ...
No comment yet